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In the United States, most reported cases of babesiosis
have been caused by Babesia microti and acquired in the
northeast. Although three cases of babesiosis acquired in New
Jersey were recently described by others, babesiosis has not
been widely known to be endemic in New Jersey. We describe
a case of babesiosis acquired in New Jersey in 1999 in an oth-
erwise healthy 53-year-old woman who developed life-threat-
ening disease. We also provide composite data on 40 cases of
babesiosis acquired from 1993 through 2001 in New Jersey.
The 40 cases include the one we describe, the three cases pre-
viously described, and 36 other cases reported to public health
agencies. The 40 cases were acquired in eight (38.1%) of the
21 counties in the state. Babesiosis, a potentially serious
zoonosis, is endemic in New Jersey and should be considered
in the differential diagnosis of patients with fever and hemolytic
anemia, particularly in the spring, summer, and early fall. 
n the United States, most of the hundreds of reported cases of
babesiosis have been caused by Babesia microti, a parasite of
small mammals transmitted by Ixodes scapularis (deer ticks);
these ticks also transmit Borrelia burgdorferi and Anaplasma
(Ehrlichia) phagocytophila. Most reported cases of babesiosis
have been acquired in the northeast, specifically in New York,
Massachusetts, Connecticut, and Rhode Island. Another focus of
B. microti infection is in Wisconsin and Minnesota (1). 
Although three cases of babesiosis acquired in New Jersey
in 1998 were described by Eskow et al. (2), babesiosis has not
been widely known to be endemic in New Jersey. Of interest,
the index case-patient who acquired B. microti infection in the
northeast (on Nantucket Island in 1969) actually was hospital-
ized in New Jersey (3). We describe a case of babesiosis
acquired in New Jersey in 1999 and provide composite data
that include this case, the three cases previously reported by
Eskow et al. (2), and 36 other cases acquired in New Jersey
from 1993 through 2001. Our data strengthen the conclusion
that babesiosis is endemic in New Jersey. 
Methods
Case Detection and Definition
We learned of additional babesiosis cases because they
were reported to the New Jersey Department of Health and
Senior Services or because health-care providers contacted the
Centers for Disease Control and Prevention (CDC) about the
diagnosis or treatment of babesiosis. Although babesiosis is
not a nationally notifiable disease, some states have made
cases of babesiosis reportable. Cases became reportable in
New Jersey in 1985; however, reporting was discontinued in
1990 because no cases had been reported. Reporting was rein-
stated in 1995, and 1997 was the first year in which cases were
reported to the health department. 
We defined a case of babesiosis as an infection occurring in
a symptomatic person whose illness was consistent with babesi-
osis, most likely was acquired in New Jersey, and most likely
resulted from a tick bite rather than a blood transfusion. In addi-
tion, supporting laboratory data had to be provided and include
at least one of the following: identification by light microscopy
of intraerythrocytic Babesia  parasites in a peripheral blood
smear, isolation of the parasite from a whole blood specimen
(by inoculating hamsters [Mesocricetus auratus] intraperito-
neally and examining smears of blood obtained by tail snip,
weekly for up to 2 months), demonstration of B. microti DNA in
a whole blood specimen by polymerase chain reaction (PCR)
analysis at a reference laboratory, or demonstration of a Babe-
sia-specific antibody titer of at least 1:256 with an indirect fluo-
rescent antibody assay for total immunoglobulin (Ig) or IgG. If
only serologic data met the diagnostic criteria, the case was con-
sidered probable rather than confirmed.
Case Report
A previously healthy 53-year-old woman was admitted to
a community hospital on June 24, 1999, because she had had 1
week of fever (38.9°C–39.4°C), rigors, a nonproductive
cough, an occipital headache, and increasing malaise. Three
days before her hospitalization, she started therapy with
cefuroxime axetil for presumed bronchitis but did not
improve. She had a >50 pack-year history of smoking and
drank two to three beers per day. She lived in Burlington
County (Figure 1) in southcentral New Jersey and had not
traveled outside the county recently. Although she did not
recall recent exposure to deer ticks, she occasionally had seen
deer in her backyard and she gardened frequently.
On admission to the hospital, she had a temperature of
39.2°C, a blood pressure level in the 80/60 mm Hg range, and
otherwise unremarkable results on physical examination. She
was anemic and thrombocytopenic, with elevated total biliru-
bin and lactate dehydrogenase values (Table). On the basis of a
blood smear from June 24, which showed intraerythrocytic
ring forms in approximately 5% of the erythrocytes on her
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peripheral blood smear, treatment for babesiosis was begun on
June 25. The treatment included intravenous clindamycin, 900
mg three times a day, and oral quinine, 650 mg three times a
day; and she was transfused with two units of packed erythro-
cytes. Also on June 25, hypoxic respiratory failure developed,
and she was intubated. A chest radiograph showed diffuse
alveolar infiltrates, which were attributed to the adult respira-
tory distress syndrome (ARDS). 
On June 28, she was transferred to the Hospital of the Uni-
versity of Pennsylvania. When admitted, her blood pressure
was 84/52 mm Hg, despite therapy with dopamine. She contin-
ued therapy for babesiosis for a total of 15 days (the dose of
clindamycin was decreased to 600 mg three times a day on
June 28). Although the level of parasitemia had decreased to
0.3% by June 29, she had ongoing hemolysis and received six
more units of packed erythrocytes during her hospital stay
(Table). No parasites were noted on a blood smear on July 9,
the last day of antibabesial therapy. She had been successfully
weaned from inotropic blood-pressure support on July 2 and
underwent extubation on July 4.
Additional laboratory testing at CDC provided further evi-
dence that she was infected with B. microti. Serum specimens
assayed in parallel, in serial fourfold dilutions, by indirect flu-
orescent antibody testing for antibody to B. microti (4), had
titers of 1:1,024 (June 30, 1999) and 1:16 (July 16, 2000). In
addition, PCR analysis of whole blood from June 30, 1999, by
using  B. microti-specific primers (5), confirmed she was
infected with B. microti. Serologic testing performed at the
Hospital of the University of Pennsylvania by enzyme immu-
noassay for antibody to Borr. burgdorferi was negative. 
Complications during her hospitalization unrelated to
babesiosis included nosocomial pneumonia, acute tubular
necrosis from hypoperfusion, bilateral deep venous throm-
boses, pulmonary embolism, and thrombocytopenia tempo-
rally associated with the initiation of heparin therapy (Table).
On July 23, after 30 days in the hospital, she was sent home.
She was continuing to do well as of October 2002.
Composite Data
The 40 cases in our analyses include the case described
above, the three cases previously described by Eskow et al.
(2), and 36 other cases. We did not include six other reported
tick-borne cases that occurred in New Jersey residents,
because the laboratory data did not meet our criteria or infor-
mation about the probable state in which infection was
acquired was not known or provided. 
The number of reported cases of babesiosis increased over
time (Figure 2); 28 (70.0%) of the 40 cases occurred in 2000
or 2001. The 40 cases were acquired in eight (38.1%) of the
state’s 21 counties (Figure 1). Burlington County, on the inner
coastal plain, and Ocean County, on the outer coastal plain,
which are neighboring counties in southcentral New Jersey,
accounted for 25 (62.5%) of the 40 cases; these two counties
are the 7th (Ocean) and 10th (Burlington) most populous
counties in the state. None of the cases were acquired in the
northernmost or southernmost counties of New Jersey. 
Most of the cases were in elderly persons (median age, 67
years; range, 11–87 years). Over half of the cases (22 [55.0%])
were in male patients. The median date of diagnosis was July
20 (range, June 10–September 9; n=36). Two patients (5.0%)
died: an 86-year-old man with multisystem organ failure and
an 80-year-old man with ARDS. The patient whose case we
described here also developed ARDS.
The following information about the patients was not col-
lected systematically. However, three patients were reported to
be asplenic, 18 to have recalled tick bites, 34 to have been hos-
pitalized, and three to have had Lyme disease (no details avail-
able). Underlying conditions included HIV infection in one
patient, who had a CD4 count of 50; diabetes in five patients; a
history of breast or prostate cancer in three patients (no details
available); and a condition that led to chemotherapy in one
person (no details available). 
Various types of laboratory tests were used to diagnose the
40 babesiosis cases. Not all patients were tested with the same
methods. However, 34 patients had positive blood smears; for
27 of these patients, the positive smear was the only laboratory
result that met our diagnostic criteria. All three cases reported
by Eskow et al. were in patients who had negative blood
Figure 1. Map of New Jersey showing its 21 counties. The eight coun-
ties in which reported cases of babesiosis were acquired from 1993
through 2001 are shaded in gray (the darker the gray, the more cases).
The number of cases reported per county is shown under the name of
the county.RESEARCH
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smears (2). One of the two patients who had whole blood inoc-
ulated into hamsters had positive results (i.e., the hamsters
became parasitemic). Four patients had positive PCR results
from a reference laboratory; for one of these patients, these
results were the only ones that met our diagnostic criteria.
Twelve patients had serologic data that met our criteria; for
four patients, the serologic results were the only data that met
our diagnostic criteria. These cases were considered probable
rather than confirmed. CDC confirmed the diagnosis of Babe-
sia infection in 11 (27.5%) of the 40 cases; specimens from the
other 29 case-patients were not sent to CDC. 
Discussion
Our report strengthens the evidence that New Jersey is one
of the eastern states in which babesiosis is endemic. In addi-
tion, the risk for acquisition of infection is widely distributed
in the state. Whether the fact that most of the reported cases
occurred in southcentral and northcentral counties reflects the
degree of endemicity of babesiosis in various areas of New
Jersey is unknown. 
The fact that babesiosis is endemic in New Jersey is not
surprising, given that Lyme disease, the etiologic agent of
which also is transmitted by I. scapularis, is highly endemic in
New Jersey (6,7) and given the geographic proximity of New
Jersey to areas in the northeast where babesiosis is highly
endemic. In a 1996 study, of 100 I. scapularis ticks collected
in Hunterdon County, New Jersey, 43 were infected with Borr.
burgdorferi, 5 were infected with B. microti, and 2 were
infected with both organisms (8). 
The increase in reported cases of babesiosis, which began
in 1998 (Figure 2) and was even more notable in 2000 and
2001, could indicate an increased risk for B. microti infection
and illness. If true, possible reasons for the increased risk could
include a growing abundance of local I. scapularis populations
or the introduction of a more virulent strain of B. microti (9).
However, the increased numbers of reported cases could sim-
ply represent an increased awareness of the disease and
increased reporting. Even so, the 40 cases of babesiosis that we
tallied probably represent only a fraction of the clinical cases
of  B. microti infection acquired in New Jersey from 1993
Table. Clinical data on selected dates for a patient who acquired babesiosis in New Jersey
Date
Temperature 
(°C)
Hematocrit 
(%)
Leukocyte 
count 
(109/L)
Platelet
 count 
(109/L)
Parasitemia 
level (%)
Creatinine 
level 
(mg/dL)a
Total 
bilirubin level 
(mg/dL)a
Lactate 
dehydrogenase 
level (U/L)a Comments
June 24 39.2 25 4.6b 92 5.0 1.1 2.2c 646 Hospitalized
June 25 38.2 — — — — — 3.2 — Antibabesial therapy 
started; intubated;
2 units packed erythrocytes 
transfused
June 26 40.0 31 6.0 55 — 1.1 2.9 1,019 —
June 28 — 28 8.6 93 — 0.9 2.7d — Transferred to the Hospital of 
the University of Pennsylvania
June 29 39.2 27 9.0 99 0.3 1.9 — 5,147 —
June 30 38.3 22 7.9 109 — 2.8 1.5 4,047 2 units packed erythrocytes 
transfused
July 1 38.7 26 9.7 138 — 3.5 1.9 4,140 —
July 2 38.0 26 9.0 139 — 2.9 1.6 3,669 2 units packed erythrocytes 
transfused
July 4 38.7 29 14.7 144 — 2.2 2.2 2,864 Extubated
July 7 38.2 28 19.3 277 — 1.5 — — Developed nosocomial 
pneumonia
July 8 38.1 23 16.3 308 — 1.7 2.1 2,008 2 units packed erythrocytes 
transfused
July 9 38.3 31 11.7 300 0.0 1.8 — — Antibabesial therapy stopped
July 11  Afebrile 28 15.3 310 — 1.8 — — —
July 16 Afebrile 29 15.8 396 — 1.5 1.0 — —
July 19 Afebrile 30 15.8 322 — 1.6 — 1,081 —
July 21 Afebrile 26 12.3 71 — 1.9 — — Developed heparin-associated 
thrombocytopenia
July 23 Afebrile 28 12.4 50 — — — — Sent home
aNormal ranges for community hospital (June 24–June 27): creatinine level, 0.6–1.3 mg/dL; total bilirubin level, 0.2–1.0 mg/dL; indirect bilirubin level, 0.2–1.2 mg/dL; lactate dehy-
drogenase level, 91–180 U/L. Normal ranges for the Hospital of the University of Pennsylvania: creatinine level, 0.6–1.0 mg/dL; total bilirubin level, 0.0–1.2 mg/dL; indirect bilirubin 
level, 0.0-1.2 mg/dL; lactate dehydrogenase level, 313–618 U/L.
b25% segmented neutrophils, 33% band forms, 22% lymphocytes, 2% atypical lymphocytes, 8% monocytes.
cIndirect bilirubin level, 1.4 mg/dL.
dIndirect bilirubin level, 2.1 mg/dL; serum haptoglobin level, <38 mg/dL (normal range, 60–160 mg/dL); results of direct and indirect Coombs test, negative.Emerging Infectious Diseases  •  Vol. 9, No. 2, February 2003 187
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through 2001. Presumably, other symptomatic cases (as well as
many more subclinical cases) occurred but were not diagnosed
or reported. In fact, several other possible symptomatic cases
were reported that we did not count because we received insuf-
ficient information about them. Also, as is commonly true for
surveillance data, the amount and quality of the information
provided to the health department and CDC about the cases
varied widely; some of the information might have been inac-
curate, and not all of the cases were confirmed by reference
laboratories (e.g., not all of the blood smears that were reported
as positive were reexamined by a reference laboratory). 
The laboratory tests CDC offers for babesiosis, when indi-
cated, include examination of blood smears, hamster inocula-
tion, and PCR (5) for parasitologic diagnosis and an indirect
fluorescent antibody assay for total immunoglobulin for sero-
logic diagnosis (4). Using PCR for detection of DNA from
Babesia spp. has not yet become a routine diagnostic method,
and the analysis should be conducted by experienced reference
laboratories. 
Immunoblot testing for IgG and IgM is investigational.
However, an immunoblot test for IgG performed well in a
recent evaluation, with a sensitivity of 96% and a specificity of
99% (10). A positive serologic result for IgM (11) is insuffi-
cient for diagnosis without a positive result for IgG. If the IgM
result is positive but the IgG result is negative, a follow-up
specimen should be tested. If IgG seroconversion is not noted,
the IgM result likely was a false positive. Future serologic test-
ing might involve recombinant and synthetic antigens (12)
rather than whole parasites or soluble antigens.
The case we described in detail demonstrates that babesio-
sis can be life threatening (1,13,14). In fact, two (5.0%) of the
40 case-patients died. In the patient we described, the follow-
ing conditions developed: severe anemia, for which she was
transfused with eight units of packed erythrocytes; hypoten-
sion that required inotropic support; ARDS, which has previ-
ously been reported (13–17); and various nosocomial
complications. The fact that she was ill for approximately 1
week before therapy for babesiosis was initiated might have
contributed to the severity of her illness. Fortunately, treatment
for babesiosis was begun soon after she was hospitalized.
Although she was treated successfully with clindamycin and
quinine, a recent clinical trial indicated that the combination of
azithromycin and atovaquone is also effective (18). However,
patients with life-threatening babesiosis were excluded from
the study. Severely ill patients, particularly those with high
levels of parasitemia (e.g., >10%), may benefit from exchange
transfusion (1,19). 
In summary, babesiosis, a potentially serious zoonosis, is
endemic in New Jersey and should be considered in the differ-
ential diagnosis of patients with fever and hemolytic anemia,
particularly in the spring, summer, and early fall. 
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